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Abbreviations 
 
AMPK, AMP-activated protein kinase 
ARA, arachidonic acid  
AT, adipose tissue 
AUC, area under the curve  
BHT, butylated hydroxytoluene  
DHA, docosahexaenoic acid  
EPA, eicosapentaenoic acid  
Fiaf, fasting-induced adipose factor 
HDoHE, hydroxydocosahexaenoic acid  
HEPE, hydroxyeicosapentaenoic acid 
HETE, hydroxyeicosatetraenoic acid 
HpEPE, hydroperoxyicosapentaenoic acid 
IGT, impaired glucose tolerance 
IR, insulin resistance 
LTB4, leukotriene B4 
PGE2, prostaglandin E2 
qRT-PCR, quantitative real-time PCR 
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Abstract 2 
Scope: The goals of this work were to test if D-fagomine, an iminosugar that reduces 3 
body weight gain, can delay the appearance of a fat-induced prediabetic state in a rat 4 
model and to explore possible mechanisms behind its functional action.  5 
Methods and results: Wistar Kyoto rats were fed a high-fat diet supplemented with D-6 
fagomine (or not; for comparison) or a standard diet (controls) for 24 weeks. The variables 7 
measured were: fasting blood glucose and insulin levels; glucose tolerance; 8 
diacylglycerols as intracellular mediators of insulin resistance in adipose tissue, liver and 9 
muscle; inflammation markers (plasma IL-6 and leptin, and liver and adipose tissue 10 
histology markers); eicosanoids from arachidonic acid as lipid mediators of 11 
inflammation; and the populations of Bacteroidetes, Firmicutes, Enterobacteriales and 12 
Bifidobacteriales in feces. We found that D-fagomine reduces fat-induced impaired 13 
glucose tolerance, inflammation markers and mediators (hepatic microgranulomas and 14 
lobular inflammation, plasma IL-6, prostaglandin E2 and leukotriene B4) while 15 
attenuating the changes in the populations of Enterobacteriales and Bifidobacteriales.  16 
Conclusion: D-Fagomine delays the development of a fat-induced prediabetic state in rats 17 
by reducing low-grade inflammation. We suggest that the anti-inflammatory effect of D-18 
fagomine may be linked to a reduction in fat-induced overpopulation of minor gut 19 
bacteria. 20 
  21 
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1 Introduction 22 
The World Health Organization estimated that 422 million adults suffered from diabetes 23 
in 2014 and 1.5 million deaths could be directly attributed to this pathology in just one 24 
year (2012). Most of the population suffering from diabetes is affected by type 2 diabetes 25 
(T2D). T2D is preceded by insulin resistance (IR): a reduced capacity to internalize 26 
glucose from the bloodstream as a result of insensitivity to insulin that may result from 27 
genetic predisposition, physical inactivity and/or obesity in both rats and humans [1]. IR 28 
brings about an increase of pancreatic insulin secretion from a greater number or size of 29 
pancreatic β-cells, which compensates the low insulin sensitivity. Then, if IR proceeds 30 
further into diabetes, a drop in insulin secretion follows, with subsequent increased fasting 31 
glucose levels and impaired glucose tolerance (IGT; high glucose levels 2 h after 32 
ingestion) as a consequence of a loss and dedifferentiation of pancreatic β-cells [1]. Three 33 
main mechanisms have been proposed to explain the pathogenesis of IR in different 34 
organs: endoplasmic reticulum stress with activation of the unfolded protein response, 35 
ectopic lipid accumulation with impairment of intracellular signaling patterns by 36 
particular lipid mediators, and systemic inflammation [2]. More recently, systemic 37 
inflammation, IR, and obesity have been linked to shifts in the populations of gut 38 
microbiota (gut “dysbiosis”) [3]. 39 
The major bacterial phyla in distal gut microbiota are Bacteroidetes and Firmicutes. A 40 
reduction in the ratio between these two phyla has been related to weight gain by the host 41 
[4, 5]. Also, an increase in the population of Enterobacteriales has been associated with 42 
diet-induced obesity [6]. A common antecedent that may link dysbiosis, obesity and IR is 43 
the induction of plasmatic endotoxemia [7], which may trigger low-grade inflammation 44 
and/or changes in energy harvest capacity [8, 9]. Other minor gut bacterial subgroups such 45 
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as Lactobacillus and Bifidobacterium may help to maintain host homeostasis [10]. 46 
Specifically, high levels of Bifidobacterium reduce diet-induced IR and inflammation [11, 47 
12].  48 
D-Fagomine (1,2-dideoxynojirimycin) is an iminosugar: a carbohydrate analog that 49 
includes an endocyclic nitrogen instead of oxygen [13]. D-Fagomine is naturally present in 50 
buckwheat (Fagopyrum esculentum Moench, Polygonaceae) and can be found in several 51 
buckwheat-based foodstuffs such as noodles, pancakes, fried dough, beer, cookies and 52 
bread [14]. D-Fagomine lowers post-prandial blood glucose in sucrose/starch loading tests 53 
[15] and it reduces elevated plasma insulin concentrations induced by a high-fat high-54 
sucrose diet in the short term (9 weeks) [16]. 55 
This study examines the long-term functional effect of D-fagomine on a fat induced 56 
prediabetic state and explores possible molecular mechanisms behind its action. 57 
  58 
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2 Materials and methods 59 
2.1 Animals 60 
 61 
A total of twenty-seven male Wistar Kyoto rats from Envigo (Indianapolis, IN, USA), 62 
aged 8-9 weeks were used. All the procedures strictly adhered to the European Union 63 
guidelines for the care and management of laboratory animals, and were under license 64 
from the Catalan authorities (reference no. DAAM7921), as approved by the Spanish 65 
CSIC Subcommittee of Bioethical Issues. 66 
 67 
2.2 Experimental design: data and sample collection 68 
 69 
The rats were kept under controlled conditions of humidity (60%), and temperature (22 ± 70 
2 ºC) with a 12 h light-12 h dark cycle. They were randomly divided into 3 dietary groups 71 
(n = 9/group): the standard (STD) group, fed a STD diet (2014 Teklad Global 14% 72 
Protein) from Envigo; the high-fat (HF) group fed a HF diet (TD.08811 45% kcal Fat) 73 
from Envigo; and the group fed the HF diet supplemented with 0.96 g of D-fagomine (> 74 
98% from Bioglane SLNE; Barcelona, Spain) per kg of feed (HF+FG group). The dose 75 
of D-fagomine corresponded that used in post-prandial sucrose/starch loading tests (2 76 
mg/g sucrose) [15]. All the groups were fed ad libitum with free access to water.  77 
Feed consumption was monitored daily and body weight was measured weekly 78 
throughout the experiment. Energy intake was calculated as estimates of metabolizable 79 
energy based on the Atwater factors, assigning 4 kcal/g protein, 9 kcal/g fat, and 4 kcal/g 80 
available carbohydrate.  81 
Fecal samples were collected by abdominal massage at weeks 9, 20 and 24. The energy 82 
content of the feces from week 20 was determined by differential scanning calorimetry 83 
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(25-600 ºC in an O2 atmosphere, 10 ºC/min) by means of a thermogravimetric analyzer 84 
TGA/SDTA 851e (Mettler Toledo; Columbus, OH, USA) with an integrated SDTA 85 
signal. 86 
At weeks 10 and 16, blood samples were collected from the saphenous vein after 87 
overnight fasting, and plasma was separated by centrifugation and stored at −80 °C until 88 
analysis.  89 
At the end of the experiment, the rats were fasted overnight and anesthetized 90 
intraperitoneally with ketamine and xylazine (80 and 10 mg/kg body weight, 91 
respectively). Blood was collected by cardiac puncture then plasma was immediately 92 
obtained by centrifugation and stored at −80 ºC until analysis. Perigonadal adipose tissue 93 
(AT), liver and quadriceps (muscular tissue) were removed, weighed and cut into small 94 
pieces. One part of the liver was fixed in 10% formalin for histological analysis. The rest 95 
of the liver as well as the muscle and AT samples were washed with 0.9% NaCl solution 96 
and stored at −80 ºC for diacylglycerol (DAG) analysis. 97 
 98 
2.3. Plasma lipid profile 99 
Plasma total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides were 100 
measured using a spectrophotometric method and the corresponding kits from Spinreact 101 
(Girona, Spain) as described by Bucolo et al. [17, 18] 102 
 103 
2.3 Plasma insulin, glucose and oral glucose tolerance test 104 
 105 
Plasma insulin levels were measured using Milliplex xMAP multiplex technology on a 106 
Luminex xMAP instrument (Millipore, Austin, TX, USA) at weeks 10 and 16. Milliplex 107 
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Analyst 5.1 (Vigenetech, Carlisle, PA, USA) software was used for data analysis. The 108 
standard curve was generated in the range 69-50,000 pg/mL. 109 
At weeks 13 and 21, an oral glucose tolerance test (OGTT) was performed on fasted 110 
animals. A solution of glucose (1 g/kg body weight) was administered to the rats by oral 111 
gavage. Blood glucose concentration was measured by the enzyme electrode method 112 
using an Ascensia ELITE XL blood glucose meter (Bayer Consumer Care AG; Basel, 113 
Switzerland) before the experiment and 15, 30, 45, 60, 90 and 120 min after glucose 114 
intake. Fasting glucose concentration was measured by the same method at weeks 10 and 115 
16. 116 
 117 
2.4 Diacylglycerols in perigonadal adipose tissue, liver and muscle 118 
 119 
Frozen samples were weighted and sonicated (SFX150 Sonifier; Emerson Industrial 120 
Automation, St. Louis, MO, USA) until total homogenization. DAG extracts were 121 
prepared and analyzed using the method described by Simbari et al. [19] with some 122 
modifications. The mixtures were fortified with an internal standard (1,3-17:0 D5 DG, 123 
Avanti Polar Lipids Inc., Alabaster, AL, USA; 200 pmol) and incubated overnight at 48 124 
ºC. After solvent evaporation, the samples were suspended in methanol, centrifuged 125 
(9390 g, 3 min) and the supernatants were loaded into an Acquity UPLC system 126 
connected to an LCT Premier orthogonal accelerated time-of-flight mass spectrometer 127 
(Waters, Milford, MA, USA), which was operated in positive ESI mode (LC-TOF-MS). 128 
Full-scan spectra from 50 to 1,500 Da were acquired, and individual spectra were summed 129 
to produce data points of 0.2 s each. Mass accuracy and precision were maintained by 130 
using an independent reference spray (leucine enkephalin) via the LockSpray 131 
interference. A C8 Acquity UPLC-bridged ethylene hybrid 100 x 2.1 mm inner diameter, 132 
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1.7 m column (Waters) was used in the separation step. The samples (8 µL) were eluted 133 
with a binary system consisting of 0.2% (v/v) formic acid, 2 mM ammonium formate in 134 
water [A] and in methanol [B] at 30 ºC under linear gradient conditions: 0 min, 80% B; 3 135 
min, 90% B; 6 min, 90% B; 15 min, 99% B; 18 min, 99% B; 20 min, 80% B; and 22 min, 136 
80% B. The flow rate was 0.3 mL/min. Quantification was carried out using the extracted 137 
ion chromatogram of each compound, across 50 mDa windows. The linear range was 138 
determined by injecting mixtures of internal standards. DGA content was calculated as 139 
DAG 16:0, 16:0 equivalents. 140 
 141 
2.5 Liver and adipose tissue histology  142 
 143 
Fixed liver and AT were dehydrated in alcohol and embedded in paraffin (Panreac 144 
Quimica SLU; Barcelona, Spain), then cut into 3 µm thick slices, using a steel knife 145 
mounted in a microtome (HM 355S Rotary Microtome; Thermo Fisher Scientific, 146 
Waltham, MA, USA). Sections were stained with hematoxylin (hematoxylin solution 147 
modified in accordance with Gill III for microscopy; Merck KGaA, Darmstadt, 148 
Germany)/eosin (Pharmacy Service of Puerta del Mar Hospital, Cádiz, Spain) then 149 
viewed under a light microscope (NIKON Eclipse 80i; NIKON Corporation, Minato, 150 
Japan). Variables were graded following the method described by Taltavull et al. [20] using 151 
observation of the entire field of the tissue preparations. Liver: steatosis, 0 (< 5%), 1 (5%-152 
33%), 2 (33%-66%), or 3 (> 66%); steatosis localization, 0 (absence), 1 (periportal), and 153 
2 (non-zonal); lobular inflammation with lymphoplasmacytic inflammatory infiltration, 154 
0 (absence), 1 (1-2 foci), 2 (2-4 foci), or 3 (> 4 foci); and the presence of 155 
microgranulomas, 0 (absence) or 1 (presence). AT: adipocyte hypertrophy, 0 (absence) 156 
or 1 (presence); macrophages 0 (absence) or 1 (presence); mast cells, 0 (absence) or 1 157 
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(presence); and adipose tissue inflammation with lymphoplasmacytic inflammatory 158 
infiltration, 0 (absence) or 1 (presence). 159 
 160 
2.6 Biomarkers and lipid mediators of inflammation in plasma 161 
 162 
Plasma IL-6 and leptin levels were measured using Milliplex xMAP multiplex technology 163 
(Millipore) on a Luminex xMAP instrument.  164 
Lipid mediators derived from arachidonic acid (ARA), eicosapentaenoic acid (EPA) and 165 
docosahexaenoic acid (DHA) were determined in plasma using a method modified from 166 
Dasilva et al. [21]. Briefly, plasma samples (90 µL) were diluted in cold 0.05% BHT in 167 
methanol/water (3:7) (1 mL) and spiked with the internal standard (12HETE-d8, Cayman 168 
Chemicals; Ann Arbor, MI, USA). Then, the samples were centrifuged (Avanti J25, 169 
Beckman Coulter; Brea, CA, USA) (800 g, 10 min) at 4 ºC. The supernatants were 170 
purified by solid-phase extraction. 171 
The LC-MS/MS analyzer used was an Agilent 1260 Series (Agilent; Palo Alto, CA, USA) 172 
chromatograph coupled to an LTQ Velos Pro dual-pressure linear ion trap mass 173 
spectrometer (Thermo Fisher; Rockford, IL, USA) operated in negative ESI mode.	A 174 
C18-Symmetry 150 × 2.1 mm inner diameter, 3.5 μm column (Waters) was used with a 175 
C18 4 × 2 mm guard cartridge (Phenomenex; Torrance, CA, USA) in the separation step. 176 
Samples (10 µL) were eluted with a binary system of 0.02% formic acid in water [A] and 177 
in methanol [B]. The gradient was: 1 min, 60% B; 2 min, 60% B; 12 min, 80% B; 13 min, 178 
80% B; 23 min, 100% B; 25 min, 100% B; and 30 min, 60% B. The flow rate was 0.2 179 
mL/min. LC-MS/MS details are provided in Supporting Information Table S1. 180 
 181 
2.7 Fecal microbiota 182 
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 183 
The levels of total bacteria and Bacteroidetes, Firmicutes, Enterobacteriales, 184 
Bifidobacteria and Lactobacilliales were estimated from fecal DNA by quantitative real-185 
time PCR (qRT-PCR). DNA was extracted from the feces using QIAamp® DNA Stool 186 
Mini Kit from QIAGEN (Hilden, Germany) and its concentration was quantified using a 187 
Nanodrop 8000 Spectrophotometer (ThermoScientific; Waltham, MA, USA). All DNA 188 
samples were diluted to 20 ng/µL. The qRT-PCR experiments were carried out using a 189 
LightCycler® 480 II (Roche; Basel, Switzerland). 190 
Each qRT-PCR well was run in triplicate and contained a total of 20 µL: 18 µL of Master 191 
Mix (10 µL of 2X SYBR, 1 µL of each (forward and reverse) corresponding primer and 192 
6 µL of water) and 2 µL of DNA sample. All reactions were paralleled by analysis of a 193 
nontemplate control (water) and a positive control. The primers and annealing 194 
temperatures are detailed in Supporting Information Table S2. 195 
The qRT-PCR cycling conditions were: 10 s at 95 ºC, then 45 cycles of 5 s at 95 ºC, 30 s 196 
at primer-specific annealing temperature (Supporting Information Table S2), and 30 s at 197 
72 ºC (extension). Following amplification, to determine the specificity of the qRT-PCR, 198 
melting curve analysis was carried out by treatment for 2 s at 95 ºC, 15 s at 65 ºC, and 199 
then continuous increase of temperature up to 95 ºC (0.11 ºC/s), with five fluorescence 200 
recordings per ºC. The relative DNA abundances for the different genes were calculated 201 
from the second derivative maximum of their respective amplification curves (Cp, 202 
calculated in triplicate) by considering Cp values to be proportional to the dual logarithm 203 
of the inverse of the specific DNA concentration, according to the equation: 204 
[DNAa]/[DNAb] = 2Cpb-Cpa [22]. Total bacteria was normalized as 16S rRNA gene copies 205 
per mg of wet feces (copies/mg).  206 
 207 
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2.8 Statistical analysis 208 
 209 
All data manipulation, statistical analysis and figure construction were performed using 210 
Graph Pad Prism 5 (Graph Pad Software, Inc., San Diego, CA, USA). The results of the 211 
quantitative measurements are expressed as mean values with their standard errors 212 
(SEM). Normal distributions and the heterogeneity of data were evaluated and their 213 
statistical significance was determined by one- or two-way ANOVA, and Tukey’s 214 
multiple comparison test was used for mean comparisons. The results from qualitative 215 
measurements (histology) are expressed in frequencies (percentage of animals that 216 
present the variable, or do not) and their statistical significance was determined using 217 
contingency tables and χ2 statistics. Differences were considered significant when P < 218 
0.05 and were considered to indicate a tendency when 0.05 < P < 0.1. 219 
220 
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3 Results 221 
3.1 Feed intake, body weight, and lipid profile 222 
Feed/energy intake and body weight were monitored throughout the study (Table 1; 223 
Supporting Information Fig. S1). Rats fed the two high-energy-dense diets (HF and 224 
HF+FG) consumed significantly less feed (P < 0.05) and more energy (P < 0.05) than 225 
those in the STD group (Table 1). Based on feed intake, the mean daily dose of D-226 
fagomine was 2.9 mg/100 g body weight. As observed in previous studies, D-fagomine 227 
supplementation did not modify feed intake [16]. The energy excreted, proportional to the 228 
SDTA signal obtained by thermal analysis, was similar in both the STD and HF groups 229 
and significantly higher (P < 0.05) in animals fed HF and D-fagomine. This result may be 230 
explained by the inhibitory activity of D-fagomine on intestinal disaccharidases [15], which 231 
would result in the excretion of some undigested sucrose. 232 
Body weight was similar in all the groups at the beginning (236.1 g, SEM 3.2). After 7 233 
weeks, body weight in the HF group (374.3 g, SEM 10.0) was significantly higher (P < 234 
0.05) than in the STD group (320.3 g, SEM 9.1); while the body weight increase in the 235 
HF+FG group only reached statistical difference (P < 0.05) with respect to the STD group 236 
five weeks later: after 12 weeks of diet (Supporting Information Fig. S1). At the end of 237 
the study, the HF group gained 29% more weight than those given the STD diet (537.9 g, 238 
SEM 15.1 vs 416.4 g, SEM 12.9 STD group) while animals supplemented with D-239 
fagomine showed a tendency to gain less weight (20%: 499.9 g, SEM 15.7, P = 0.06 vs 240 
the HF group) (Table 1). The plasma lipid profile presented values within normal ranges 241 
with some differences between groups (Supporting Information Table S3).  242 
 243 
 244 
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3.2 Glycemic status 245 
 246 
Fasting plasma glucose and insulin were measured at week 10, 16, and at the end of the 247 
study (Fig. 1). Fasting glucose levels in the HF group were higher (P < 0.001) than those 248 
in the STD group (Fig. 1a) already from week 10. D-Fagomine supplementation reduced 249 
this increase from week 16 to levels similar to those in the STD group (P < 0.05 vs the 250 
HF group at week 21; Fig. 1a). Fasting glucose levels were below 80 mg/dL in all the 251 
groups at all times. Fasting plasma insulin was higher in both groups fed the HF diet at 252 
weeks 10 and 16 (P < 0.05; Fig. 1b). At the end of the study (week 24), insulin levels in 253 
the HF group dropped significantly (P < 0.05) while the group supplemented with D-254 
fagomine still presented significantly higher insulin concentrations (P < 0.01; Fig. 1b).  255 
The OGTT was performed twice during the study, after 13 and 21 weeks (Fig. 2). In the 256 
first test, the levels of postprandial glucose in the HF group were significantly (P < 0.001) 257 
higher than those in the other two groups (STD and HF+FG) 30, 45 and 60 min after 258 
administration, with levels of ≥ 140 mg/dL (Fig. 2a). The area under the curve (AUC) 259 
corresponding to the HF group was significantly greater (P < 0.001) than that for the STD 260 
and HF+FG groups, which presented no significant differences. By the end of the study 261 
(week 21, Fig. 2b) plasma glucose concentrations in the group supplemented with D-262 
fagomine were still lower than those in the HF group, but only significantly lower (P < 263 
0.05) 30 min after glucose intake. The AUC for the HF+FG and STD groups were not 264 
significantly different. 265 
 266 
3.3 Biomarkers and lipid mediators of inflammation in plasma 267 
 268 
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Plasma concentration of IL-6 after 10 and 16 weeks of intervention was higher in animals 269 
fed HF diets (P < 0.05) than in animals fed the STD diet (Table 2). D-Fagomine showed 270 
a tendency (P = 0.07) to reduce the levels of plasma IL-6 at week 16. The plasma leptin 271 
concentration was higher in both groups fed HF diets (P < 0.001).  272 
The levels of ARA-derived pro-inflammatory eicosanoids as well as eicosanoids and 273 
docosanoids derived from EPA and DHA, respectively, were measured by LC-MS/MS in 274 
plasma samples collected at the end of the study (Table 2). The plasma concentration of 275 
PGE2 significantly increased in the HF group (P < 0.05) compared to the STD group. The 276 
levels of pro-inflammatory PGE2 and LTB4 were similar in the STD and HF+FG groups. 277 
No differences were detected in the levels of other eicosanoids or docosanoids (Table 2). 278 
 279 
3.4 Diacylglycerols in perigonadal adipose tissue, liver and muscle 280 
 281 
IR-related intracellular signaling lipid mediator DAGs were measured in perigonadal AT, 282 
liver and muscle by LC-TOF-MS from the samples taken at the end of the study (Fig. 3). 283 
There was no increase in the amounts of total DAGs or in some of the relevant structures, 284 
namely DAG 34:1 (putatively 1-palmitoyl-2-oleoyl-sn-glycerol), DAG 36:2 (putatively 285 
1-stearoyl-2-linoleoyl-sn-glycerol) and DAG 38:4 (putatively 1-stearoyl-2-arachidonoyl-286 
sn-glycerol) in the HF group compared to the STD one. The levels of total DAGs in AT 287 
as well as of DAG 34:1 in AT and DAG 38:4 in AT and muscle were even significantly 288 
lower in the HF group. D-Fagomine supplementation did not induce any significant 289 
change in the levels of DAGs with respect to the HF group.  290 
 291 
3.5 Liver and adipose tissue histology 292 
 293 
 
 
17 
 
Steatosis, lobular inflammation and microgranulomas were determined in liver by 294 
histology (Fig. 4). Neither high-fat diet induced steatosis to any significant extent. The 295 
inflammation and microgranulomas of animals fed HF were significantly higher (P < 296 
0.001) than those of the STD and HF+FG groups (Fig. 4e, g). The livers sections obtained 297 
from animals in the HF group showed lobular inflammation with lymphoplasmacytic 298 
inflammatory infiltration around the blood vessels (e.g. Fig. 4b). In contrast, such 299 
infiltration was scarce and smaller in extent in sections from livers pertaining to the group 300 
supplemented with D-fagomine (e.g. Fig. 4c).  301 
Adipocytes were larger in the AT of animals fed the HF diets than the STD group 302 
(Supporting Information Figure S2a, b, d); while no differences were detected between 303 
the HF and HF+FG groups (Supporting Information Figure S2b, c). AT inflammation was 304 
not detected in any of the groups (Supporting Information Figure S2g). 305 
 306 
3.6 Subpopulations of gut microbiota 307 
 308 
The relative proportions of several bacterial groups of the gut microbiota were evaluated 309 
at weeks 9 and 24 (Fig. 5). The Bacteroidetes:Firmicutes ratio (Fig. 5a) was significantly 310 
reduced (P < 0.01) in both high-fat diet groups and the presence of D-fagomine in the diet 311 
made no difference. The proportion of Enterobacteriales (Fig. 5b) significantly (P < 0.05) 312 
increased in the HF group with respect to the STD group. The increase observed in the 313 
group supplemented with D-fagomine was not significant. The relative populations of 314 
Bifidobacteriales decreased as the animals grew older (P < 0.01 vs STD week 9; Fig. 5c) 315 
and some differences were detected between the groups. The HF diet significantly 316 
reduced the population of Bifidobacteriales already at week 9 (P < 0.05) independently 317 
of supplementation while D-fagomine, which showed a tendency to counteract the age- 318 
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and diet-related losses of Bifidobacteriales that was only significant (P < 0.05) at the end 319 
of the intervention (week 24).  320 
 321 
  322 
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4 Discussion 323 
The present study examines the long-term functional effects of D-fagomine on the 324 
preservation of glucose/insulin homeostasis and explores possible mechanisms of action 325 
for them in a rat model of diet-induced prediabetes. The prediabetic state was induced in 326 
male Wistar Kyoto rats by feeding them a HF diet and the effects of D-fagomine were 327 
observed over a period of 24 weeks. In agreement with preceding short-term studies (5 328 
and 9 weeks) in Sprague-Dawley rats [16, 23], D-fagomine partially counteracted the body 329 
weight gain induced by the HF diet in the long term (Supporting Information Fig. S1). 330 
Plasma insulin levels also increased in animals fed the HF diet after 10 weeks of 331 
intervention (Fig. 1). High plasma insulin levels define the first of the five stages of 332 
diabetes proposed by Weir and Bonner-Weir for both rats and humans [1]. This 333 
compensation stage is characterized by increased overall rates of insulin secretion, via a 334 
greater number or size of pancreatic β-cells, in response to loss of insulin sensitivity in 335 
tissues. D-Fagomine, which had shown a tendency to reduce insulin levels in the short 336 
term [16, 23], did not have an influence on insulin levels after 10 weeks of our intervention 337 
(Fig. 1b).  338 
Later on, at the end of the study, the levels of fasting insulin in the HF group (without 339 
supplementation) dropped significantly (Fig. 1b), while fasting glucose levels were still 340 
moderately high (Fig. 1a). This situation is compatible with the second stage in the 341 
diabetes progression, which is characterized by a loss of β-cell mass and disruption of 342 
pancreatic function [1]. Animals supplemented with D-fagomine did not seem to reach this 343 
second prediabetic stage, as their insulin levels remained high (Fig. 1b) and their fasting 344 
glucose levels were similar to those of the STD group (Fig. 1a). The second prediabetic 345 
state is also compatible with the IGT recorded in rats fed the HF diet, which already 346 
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showed the classic plateau-like prediabetic curve after just 13 weeks. D-Fagomine 347 
counteracted this fat-induced IGT pattern as the supplemented rats removed glucose from 348 
their blood at a normal rate (Fig. 2a, b). By the end of the study (21 weeks), the AUC for 349 
the HF+FG and STD groups were still not significantly different. The evidence presented 350 
here, together with our previous observations of the short-term reduction in the early 351 
increase of fasting insulin concentration [16, 23], shows that rats supplemented with D-352 
fagomine always seem to be one step behind in the development of diet-induced 353 
prediabetes.   354 
We next considered through what mechanism or mechanisms D-fagomine exerts this 355 
functional metabolic effect. As D-fagomine reduced IGT more dramatically than it 356 
reduced body weight gain, we hypothesized that it may delay the development of diabetes 357 
in Wistar Kyoto rats by a mechanism that is not directly dependent on lipid accumulation. 358 
The results from our DAG analysis and histological study support this explanation. IR 359 
has been linked to ectopic fat through the action of DAGs, which are intermediates of 360 
lipid metabolism with the capacity to impair intracellular insulin signaling in both liver 361 
and muscle [2]. It has been proposed that DAGs interrupt the translocation of the glucose 362 
transporter GLUT4 to the plasma membrane by modifying the phosphorylation pattern of 363 
the intracellular insulin receptor substrate (IRS) after attaching to protein kinase C [24]. 364 
We evaluated total DAGs and the levels of selected molecular species in these two organs 365 
as well as in AT (Fig. 3). As there is no information to date as to what particular DAG 366 
species might impair insulin signaling, particular DAGs were chosen on the basis of their 367 
selective interaction with the cellular PKC–Ca2+ signaling network [25]. Systemic IR in 368 
our model does not seem to be triggered by DAG-mediated impairment of insulin 369 
signaling, as the levels of total and selected DAGs in AT, liver and muscle did not 370 
increase in either of the groups fed the high-fat diet (Figure 3); in fact DAG levels were 371 
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even lower in some instances. The liver histology supported the hypothesis that direct 372 
lipid-mediated loss of insulin sensitivity was probably not a triggering factor of the early 373 
prediabetic stage in our model, as significant steatosis was not detected (Fig. 4a, b, c). In 374 
contrast, strong lymphocyte infiltration indicated inflammation around the blood vessels 375 
(Fig. 4c) which was greatly attenuated in animals supplemented with D-fagomine (Fig. 376 
4d). Lobular inflammation and numbers of microgranulomas were significantly higher in 377 
the HF group than in the STD group, while these levels in animals supplemented with D-378 
fagomine were no different from those in the STD group (Fig. 4a). The histology did not 379 
detect any sign of inflammation in AT and D-fagomine did not have any observable effect 380 
of fat-induced adipocyte hypertrophy (Supporting Information Fig. S3). All these results 381 
suggest that D-fagomine has a functional effect on HF diet-induced low-grade systemic 382 
inflammation that is independent of lipid accumulation. This hypothesis is supported by 383 
our additional measurements of the systemic inflammatory marker IL-6 and its related 384 
eicosanoid PGE2, a strong proinflammatory secondary metabolite from oxidation of ARA 385 
catalyzed by cyclooxygenase-2 (COX-2) [26] which induces the production of IL-6 via 386 
macrophages [27]. The levels of IL-6 and PGE2 were significantly higher in the HF group 387 
than in the STD group and were significantly reduced in the HF+FG group (Table 2). 388 
Also, the levels of LTB4, another pro-inflammatory ARA-derived metabolite, were 389 
significantly lower in the supplemented group compared to the HF group (Table 2). The 390 
fact that no differences were detected in the levels of putatively anti-inflammatory EPA- 391 
and DHA-derived eicosanoids and docosanoids (Table 2) suggests that D-fagomine exerts 392 
its functional effect when inflammation first occurs and not by activating anti-393 
inflammatory pathways.  394 
We next turned to how D-fagomine counteracts fat-induced low-grade inflammation. Gut 395 
microbiota may be the answer, or at least part of the answer. Gut dysbiosis is known to 396 
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induce endotoxemia and low-grade inflammation in the host [3] through disruption of the 397 
intestinal barrier properties and release of pro-inflammatory molecules, such as LPS, into 398 
the bloodstream [28]. [26]Chronic subclinical inflammation has been associated with insulin 399 
insensitivity [29] and suggested as a link between gut dysbiosis and early IR [7, 11, 28]. We 400 
have already suggested that the effect of D-fagomine on body weight gain and glycemic 401 
status may be related to a reduction in the overgrowth of gut Enterobacteriales induced 402 
by a high-energy-dense diet in the short term (up to 5 weeks) [23]. The results presented 403 
here show that this explanation may hold in the long term, as the population of 404 
Enterobacteriales experiences experienced no significant changes throughout this study 405 
(Fig. 5b). Moreover, D-fagomine also showed a tendency to counteract the reduction in 406 
Bifidobacterium induced by the HF diet and age (HF and STD groups at week 24, Fig. 407 
5c). The action of D-fagomine on Bifidobacterium may be connected to its capacity to 408 
eliminate Enterobacteriales, as the populations of these subgroups appear to be inversely 409 
related [30]. The hypothesis that D-fagomine exerts its anti-inflammatory and anti-diabetic 410 
action by balancing the populations of enterobacteria and bifidobacteria is backed by 411 
previous observations by others that link enterobacteria to endotoxemia [6] and 412 
bifidobacteria to a reduced impact of fat on diet-induced diabetes [11]. Bifidobacteria have 413 
also been inversely associated with obesity and age [31].  414 
We also evaluated variations in the populations of Bacteroidetes and Firmicutes: the main 415 
two bacterial phyla in the intestinal tract (Fig. 5a). A reduction in the 416 
Bacteroidetes:Firmicutes ratio has been related to a shift from lean to fat phenotypes in 417 
both rats and humans [9, 32].  Low levels of fasting-induced adipose factor (Fiaf) and 418 
phosphorylated AMP-activated protein kinase (AMPK) may be responsible for the lipid 419 
accumulation effect associated with changes in gut microbiota [33]. We show here that a 420 
HF diet can reduce the Bacteroidetes:Firmicutes ratio concomitantly with a significant 421 
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gain in body weight (Fig. 5a, Supporting Information Fig. S1) while D-fagomine does not 422 
appear to modify this change (Fig. 5a). This observation confirms that the moderate effect 423 
of D-fagomine on weight gain might be associated with the contribution from minor 424 
components of gut microbiota (e.g. Enterobacteriales) rather than with changes in the 425 
main phyla.  426 
The observation that the effects of D-fagomine on fat-induced changes in 427 
Enterobacteriales and Bifidobacteriales were moderate compared to the more dramatic 428 
effects on glucose tolerance and inflammation suggests that other putatively 429 
proinflammatory microorganisms may be involved. A more thorough examination of the 430 
composition of gut microbiota, the gut barrier function and the role of other mediators 431 
(e.g. biliary acids) in animals fed HF diets supplemented, or not, with D-fagomine would 432 
be the next step to take along this line of enquiry. Thus, D-fagomine may help to shed 433 
more light on the complex relationships between gut microbiota and metabolic 434 
alterations.  435 
In summary, a very early effect of D-fagomine against fat-induced systemic low-grade 436 
inflammation would explain why animals fed D-fagomine are always one step behind in 437 
the progression of prediabetes: first against the loss of insulin sensitivity, then against loss 438 
of β-cell mass and disruption of pancreatic function. This effect may be attributed, at least 439 
in part, to a tendency to counteract the changes induced by a high-fat diet in the 440 
populations of gut bacterial subgroups such as Enterobacteriales and Bifidobacteriales. 441 
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Table 1.- Mean feed and energy intakes, energy excreted in feces and final body weight 
of WKY rats fed the experimental diets for 24 weeks 
 STD HF HF+FG 
 Mean SEM Mean SEM Mean SEM
Feed intake 
(g/day/100 g body 
weight) 
4.8 0.7 3.0* 0.7 2.9* 0.5 
Energy intakea 
(kcal/day/100 g body 
weight) 
14.3 0.2 17.5* 0.2 19.0* 0.2 
Energy in feces 
(ks ºC/g)b 
327.0 17.6 381.6 29.5 426.9* 18.4
Body weight at  
week 24 (g)  
416.4 12.9 537.9*** 15.1 499.9**† 15.7
 
* P < 0.05, ** P < 0.01 and *** P < 0.001 vs STD group, † P = 0.06 vs HF group. 
a estimated as metabolizable energy based on the Atwater factors: 4 kcal/g protein, 9 
kcal/g fat, and 4 kcal/g available carbohydrate. 
b integrated SDTA signal proportional to energy. 
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Table 2.- Plasma biomarkers and lipid mediators of inflammation  
  STD HF HF+FG 
  Mean SEM Mean SEM Mean SEM 
IL-6 (pg/mL)  
wk 10 47.3 19.6 193.9* 26.6 176.2 59.3 
wk 16 44.4 24.4 215.4** 47.4 149.6*† 20.8 
Leptin (pg/mL) wk 24 2444.8 303.7 8511.0** 1389.8 7984.3** 1490.7
Eicosanoids from ARA (ppb) 
PGE2  wk 24 14.4 1.7 23.3* 2.1 18.4 3.4 
LTB4  wk 24 3.5 0.7 4.4 0.7 2.7δ 0.3 
11HETE wk 24 8.2 1.1 10.2 1.4 7.8 1.1 
Eicosanoids from EPA (ppb) 
12HpEPE wk 24 14606.6 8327.7 3845.3 469.2 5034.2 956.1 
12HEPE wk 24 38.5 1.9 41.8 4.0 39.8 2.2 
5HEPE wk 24 4.4 0.1 4.5 0.1 4.3 0.0 
Docosanoids from DHA (ppb) 
17HDoHE wk 24 16.8 2.7 17.2 1.3 14.2 1.3 
11HDoHE wk 24 14.8 0.0 14.9 0.0 14.8 0.0 
4HDoHE wk 24 11.5 0.6 12.6 0.7 10.7 0.5 
 
* P < 0.05, ** P < 0.01 vs STD group, δ P < 0.05 vs HF group, † P = 0.07 vs HF group 
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Figure 1 Plasma levels of fasting glucose (a) and insulin (b) in WKY rats fed standard 
(STD), high-fat (HF), and high-fat supplemented with D-fagomine (HF+FG) diets at 
weeks 10, 16 and 21 and 24. Concentrations are represented as means with their standard 
errors. Comparisons were performed using one-way ANOVA and Tukey’s tests.  * P < 
0.05, ** P < 0.01 and *** P < 0.001 vs STD group, δ P < 0.05 vs HF group. 
 Figure 2 Time-course and area under curve (AUC) of plasma glucose concentration after 
administration of a single dose of glucose (1 g/kg body weight) to WKY rats fed a 
standard (STD), high-fat (HF), or high-fat supplemented with D-fagomine (HF+FG) diet 
at week 13 (a) and 21 (b). Values are means with their standard errors. Comparisons were 
performed using one-way ANOVA and Tukey’s tests or two-way ANOVA.  ** P < 0.01 
and *** P < 0.001 vs STD group, δ P < 0.05, δδ P < 0.01 and δδδ P < 0.001 vs HF group. 
Figure 3 Levels of DAG 34:1 (a, e, i), 36:2 (b, f, j), 38:4 (c, g, k) and total DAGs (d, h, 
l) in WKY rats fed a standard (STD), high-fat (HF), or high-fat supplemented with D-
fagomine (HF+FG) diet for 24 weeks. Values are means with their standard errors. 
Comparisons were performed using one-way ANOVA and Tukey’s tests. * P < 0.05, ** 
P < 0.01, *** P < 0.001 vs STD group.    
Figure 4 Liver histological cuts (20X) stained with hematoxylin-eosin from WKY rats 
fed a standard (STD) (a), high-fat (HF) (b), or high-fat supplemented with D-fagomine 
(HF+FG) diet (c) for 24-week histology summary (d). The STD cut (a) shows normal 
liver anatomy. The HF cut (b) shows lobular inflammation with lymphoplasmacytic 
inflammatory infiltration (arrows) around blood vessels (red). The HF+FG cut (c) shows 
slight inflammatory infiltration around a centrilobular vein (red). Values are in 
frequencies (percentage of animals that present the variable, or do not). Comparisons 
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were performed using χ2 statistics.  *** P < 0.001 vs STD group; δδδ P < 0.001 vs HF+FG 
group. 
Figure 5 Excreted intestinal bacteria measured by qRT-PCR and expressed as 
percentages of total bacteria in fecal samples from WKY rats fed a standard (STD), high-
fat (HF), or high-fat supplemented with D-fagomine (HF+FG) diet, after 9 and 24 weeks 
of nutritional intervention. Values are means with their standard errors. Comparisons 
were performed using one-way ANOVA and Tukey’s tests or two-way ANOVA.  * P < 
0.05 vs STD group; $$ P < 0.01 vs STD group from week 9. 
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Figure 4 
a)       STD b)       HF c)       HF + FG 
Steatosis
STD HF HF + FG
0
20
40
60
80
100
< 5%
5-33%
%
Microgranuloma
STD HF HF + FG
0
20
40
60
80
100
Abscence
Presence
***
%
d) 
Steatosis localization
STD HF HF + FG
0
20
40
60
80
100
Abscense
Periportal
No zonal
%
Lobular inflammation
STD HF HF + FG
0
20
40
60
80
100
Abscence
1-2 foci***
%
 
 
36 
 
  
Figure 5 
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Supporting information 
Table S1.- LC-MS/MS experimental details 
Compound Retention 
Time (min) 
MS/MS parameters 
Collision energy (eV) Quantification transition (m/z) 
PGE2 9.09 20 351→315 
LTB4 13.79 27 335→195 
11HETE 22.09 30 319→167 
12HpEPE 17.80 25 333→315 
12HEPE 18.72 27 317→179 
5HEPE 20.47 25 317→255 
17HDoHE 21.94 27 343→245 
11HDoHE 23.20 27 343→149 
4HDoHE 23.64 27 343→281 
 
The identification of the lipid mediators was done with the help of the full ion product 
spectra recorded in the range from 90 to 400 m/z units. To corroborate the identification 
and to quantify the analytes, the most intense and selective MS/MS transitions, obtained 
after direct infusion of individual standard solutions (5 μg/mL, 20 μL/min), were chosen. 
The linear dynamic range was determined by individual standards for each identified 
compound. 
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Table S2.- qRT-PCR primers and conditions 
Target bacteria Positive control 
Annealing 
temperature 
(ºC) 
Sequence (5’-3’) Reference
Total Bacteria a 65 F: ACT CCT ACG GGA GGC AGC AGT [1] 
   R: ATT ACC GCG GCT GCT GGC  
Bacteroidetes 
Bacteroides 
fragilis 
62 F: ACG CTA GCT ACA GGC TTA A [2] 
   R: ACG CTA CTT GGC TGG TTC A  
Firmicutes 
Lactobacillus 
brevis 
52 F: AGA GTT TGA TCC TGG CTC [3] 
   R: ATT ACC GCG GCT GCT GG [4] 
Enterobacteriales 
Escherichia coli 
M15 
60 F: ATG GCT GTC GTC AGC TCG T [1] 
   R: CCT ACT TCT TTT GCA ACC CAC T  
Bifidobacteriales 
Bifidobacterium 
longum 
55 F: CTC CTG GAA ACG GGT GG [5] 
   R: GGT GTT CTT CCC GAT ATC TAC A  
 
a Positive control of total bacteria was the strain with which the result was rated. 
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Table S3 Plasma lipid profile (mg/dL) in rats supplemented fed HF diet and 
supplemented with D-fagomine for 24 weeks. 
 STD HF HF+FG 
 Mean SEM Mean SEM Mean SEM 
Cholesterol 135.2 3.7 139.4 5.1 150.4* 3.4 
HDL-cholesterol 48.7 1.1 47.3 1.3 50.3 1.2 
LDL-cholesterol 23.2 1.6 24.1 1.3 29.4*δ 1.1 
Triglycerides  63.1 5.6 92.4** 7.1 116.4* 16.4 
 
* P < 0.05, ** P < 0.01 vs STD group, δ P < 0.05 vs HF group 
 
 
Figure S1.- Body weight in rats fed a standard (STD, ○), high-fat (HF, ■), or high-fat 
supplemented with D-fagomine (HF+FG, □) diet for 24 weeks. Data are presented as 
means with their standard errors. Comparisons were performed using the two-way 
ANOVA test. *P < 0.05 HF vs STD group, φ P < 0.05 HF+FG vs STD group. 
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Figure S2.- Adipose tissue histological cuts (20X) stained with hematoxylin-eosin from 
WKY rats fed a standard (STD) (a), high-fat (HF) (b), or high-fat supplemented with D-
fagomine (HF+FG) diet (c) for 24 weeks and histology summary (d). Values are in 
frequencies (percentage of animals that present or not the variable). Comparisons were 
performed using χ2 statistics.  * P < 0.05 and *** P < 0.001 vs STD group; δ P < 0.05 vs 
HF+FG group.Supporting References 
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